Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model

PLoS One. 2013;8(4):e60200. doi: 10.1371/journal.pone.0060200. Epub 2013 Apr 3.

Abstract

Parkinson's disease (PD), characterized by loss of dopaminergic neurons in the substantia nigra, is a neurodegenerative disorder of central nervous system. The present study was designed to investigate the therapeutic effect of ACS84, a hydrogen sulfide-releasing-L-Dopa derivative compound, in a 6-hydroxydopamine (6-OHDA)-induced PD model. ACS84 protected the SH-SY5Y cells against 6-OHDA-induced cell injury and oxidative stress. The protective effect resulted from stimulation of Nrf-2 nuclear translocation and promotion of anti-oxidant enzymes expression. In the 6-OHDA-induced PD rat model, intragastric administration of ACS84 relieved the movement dysfunction of the model animals. Immunofluorescence staining and High-performance liquid chromatography analysis showed that ACS84 alleviated the loss of tyrosine-hydroxylase positive neurons in the substantia nigra and the declined dopamine concentration in the injured striatums of the 6-OHDA-induced PD model. Moreover, ACS84 reversed the elevated malondialdehyde level and the decreased glutathione level in vivo. In conclusion, ACS84 may prevent neurodegeneration via the anti-oxidative mechanism and has potential therapeutic values for Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Disulfides / pharmacology
  • Disulfides / therapeutic use*
  • Dopamine / metabolism
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / physiology
  • Enzyme Induction / drug effects
  • Gene Expression / drug effects
  • Glutamate-Cysteine Ligase / genetics
  • Glutamate-Cysteine Ligase / metabolism
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism
  • Humans
  • Levodopa / analogs & derivatives*
  • Levodopa / pharmacology
  • Levodopa / therapeutic use
  • Lipid Peroxidation
  • Male
  • Oxidative Stress
  • Oxidopamine
  • Parkinson Disease, Secondary / drug therapy*
  • Parkinson Disease, Secondary / metabolism
  • Parkinson Disease, Secondary / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Response Elements
  • Substantia Nigra / drug effects
  • Substantia Nigra / pathology

Substances

  • ACS 84
  • Antioxidants
  • Antiparkinson Agents
  • Disulfides
  • Levodopa
  • Oxidopamine
  • Heme Oxygenase-1
  • Glutamate-Cysteine Ligase
  • GCLC protein, rat
  • Dopamine